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Abstract
Introduction: Pre-clinical data suggest p53-dependent anthracycline-induced apoptosis and p53-independent
taxane activity. However, dedicated clinical research has not defined a predictive role for TP53 gene mutations. The
aim of the current study was to retrospectively explore the prognosis and predictive values of TP53 somatic
mutations in the BIG 02-98 randomized phase III trial in which women with node-positive breast cancer were
treated with adjuvant doxorubicin-based chemotherapy with or without docetaxel.
Methods: The prognostic and predictive values of TP53 were analyzed in tumor samples by gene sequencing
within exons 5 to 8. Patients were classified according to p53 protein status predicted from TP53 gene sequence,
as wild-type (no TP53 variation or TP53 variations which are predicted not to modify p53 protein sequence) or
mutant (p53 nonsynonymous mutations). Mutations were subcategorized according to missense or truncating
mutations. Survival analyses were performed using the Kaplan-Meier method and log-rank test. Cox-regression
analysis was used to identify independent predictors of outcome.
Results: TP53 gene status was determined for 18% (520 of 2887) of the women enrolled in BIG 02-98. TP53 gene
variations were found in 17% (90 of 520). Nonsynonymous p53 mutations, found in 16.3% (85 of 520), were
associated with older age, ductal morphology, higher grade and hormone-receptor negativity. Of the
nonsynonymous mutations, 12.3% (64 of 520) were missense and 3.6% were truncating (19 of 520). Only truncating
mutations showed significant independent prognostic value, with an increased recurrence risk compared to
patients with non-modified p53 protein (hazard ratio = 3.21, 95% confidence interval = 1.740 to 5.935, P = 0.0002).
p53 status had no significant predictive value for response to docetaxel.
Conclusions: p53 truncating mutations were uncommon but associated with poor prognosis. No significant
predictive role for p53 status was detected.
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Introduction
One of the commonest genetic lesions in breast cancer
is mutation of the tumor suppressor gene TP53, encod-
ing the p53 protein. p53 is a transcription factor that
mediates antiproliferative mechanisms in response to
various forms of cellular stresses, in particular DNA
damage [1]. Different types of DNA damage activate
p53 through different pathways, resulting in different
responses including senescence, cell-cycle arrest and
apoptosis [2].
Experimental models of breast cancer also show that
mutation of p53 may confer an aggressive tumor beha-
vior that is not seen in p53-null models [3]. Most
mutant p53 proteins lose their ability to bind wild-type
p53 responsive elements and to regulate the expression
of p53 transcriptional targets, thus losing tumor sup-
pressor activity. However, cellular preservation of
mutated p53 may confer malignant potential such as the
capacity to metastasize, through gains of function activ-
ities (reviewed in [4] Oren and Rotter, 2010).
TP53 mutation is generally associated with a poor
prognosis, predicting poor disease-free survival (DFS)
and overall survival (OS) in breast cancer patients
[5,6]. As a predictive biomarker for treatment
response, the role of p53 remains a matter of debate.
More than a decade ago, p53 emerged as an important
factor in the activity of DNA-damaging chemothera-
pies [7]. Indeed, preclinical studies suggested p53-
dependent anthracycline-induced apoptosis and p53-
independent taxane activity [7,8]. Many clinical studies
undertaken in the last decade have sought to validate
these results. Most studies have retrospectively
assessed p53 in subgroups from biologically unselected
breast cancer trials [9-13]. Clinical data remains con-
flicting and inconclusive, and no robust predictive cor-
relation has surfaced. An important recent study is the
neoadjuvant phase III EORTC 10994/BIG 00-01 trial,
which is the only study to be prospectively powered to
assess the predictive role of p53 [14]. p53 status was
assessed using an RNA-based technique, which detects
functionally important p53 mutations using a yeast-
based assay [15]. The prognostic role of p53 was con-
firmed, but p53 was not predictive of response or
resistance to docetaxel.
The methods used to evaluate TP53 status and the
diversity of observed mutations constitute sources of
heterogeneity when analyzing the clinical impact of
mutations. More than 75% of TP53 mutations are mis-
sense mutations that produce mutant proteins, and up
to 25% of mutations are small insertions or deletions
that produce truncated proteins. Determination of p53
status by immunohistochemistry (IHC) is plagued by
high false-positive rates (overexpression of p53 wild-
type protein), high false-negative rates (truncating
mutations that stain negative), and a poor level of cor-
relation with TP53 gene mutations [9]. IHC has been
surpassed by direct DNA sequencing, functional assays
in yeast and p53 genetic signatures. Studies that have
used gene resequencing to assess TP53 status have
produced more consistent results for the prognostic
value of mutations [5,16]. However, results of gene
resequencing should be interpreted in terms of down-
stream p53 protein functions as TP53 gene mutations
impact differently on protein functions, as evidenced in
functional assays in yeast or human cells [17,18].
Indeed, assessment of the transactivation capacity of
p53 mutant proteins on different p53 target sequences
has shown great variability of activities between
mutant proteins and target sequences. Whereas hot-
spot missense mutations in the DNA-binding domain
lead to a general loss of specific transactivation capa-
city on all target sequences, missense mutations out-
side the DNA-binding domain more often retain
transcriptional activity on some promoters. Moreover,
some mutant proteins may have dominant-negative
effects on wild-type p53 or exert pro-oncogenic effects
independently of wild-type p53 [19]. The TP53 Func-
tion Database created at the International Agency for
Research on Cancer (IARC), Lyon, France, allows the
classification of TP53 mutations according to their pre-
dicted impact on p53 protein activities [19].
In the late 1990s, the Breast International Group
(BIG) 02-98 phase III randomized trial was one of many
clinical trials launched to explore the role of adjuvant
taxanes in early breast cancer (http://ClinicalTrials.gov
Identifier: NCT00174655) [20]. Improved outcomes
from the addition of taxanes to anthracycline-based
therapy have been reported in many [20-25] but not all
trials [26-28]. A recent meta-analysis reported superior
outcomes from the addition of a taxane to anthracy-
cline-based regimens in high-risk disease [29]. The abso-
lute benefit deriving from the addition of taxanes is
modest, less than 10% absolute improvement in DFS. A
key issue for clinical practice is that despite taxane ben-
efit for clinical trial cohorts, there is no predictive mar-
ker for the identification of individuals that are most
likely to benefit from taxane.
With this background of inconsistent data for clinical
utility of p53 status and absence of predictive markers
for taxane use, we undertook a retrospective, explora-
tory analysis in BIG 02-98 to investigate the prevalence,
and prognostic and predictive value of different types of
TP53 mutations. Mutation classifications based on the
IARC TP53 Function Database were used to estimate
the functional impact of TP53 gene variations, rather
than their presence per se.
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Materials and methods
Study population
The current study is a retrospective study on primary
tumor samples from a larger population of patients par-
ticipating in the clinical trial BIG 02-98. Details of
patients and methods in this trial have been described
previously by Francis et al. [20]. Briefly, BIG 02-98 was
a multicenter, randomized phase III adjuvant trial of
2887 women aged 18 to 70 years with operable, clinical
stage T1 to T3 invasive breast adenocarcinoma, with at
least one positive axillary lymph node. Between 1998
and 2001, patients were randomly assigned at a ratio of
1:1:2:2 to one of the following four adjuvant chemother-
apy regimen arms: Arm A: sequential control = four
cycles of doxorubicin (A) 75 mg/m2, followed by three
cycles of classical cyclophosphamide, methotrexate and
5-fluorouracil (CMF); Arm AC: concurrent control =
four cycles of AC 60/600 mg/m2, followed by three
cycles of CMF; Arm A-T: sequential docetaxel = three
cycles of A 75 mg/m2 followed by three cycles of doce-
taxel (T) 100 mg/m2 followed by three cycles of CMF;
Arm AT: concurrent docetaxel = four cycles of AT 50/
75 mg/m2 followed by three cycles of CMF. The
planned cumulative doxorubicin dose was higher in the
control arms (A: 300 mg/m2; AC: 240 mg/m2) than in
the docetaxel arms (A-T: 225 mg/m2; AT: 200 mg/m2).
A-T and AT had different docetaxel dose intensity but
the same cumulative dose (300 mg/m2). Endocrine ther-
apy and radiotherapy were administered according to
local guidelines. Adjuvant trastuzumab was not available.
Institutional Ethics Committees approved the protocol
at all participating sites and patients provided written
informed consent.
p53 substudy cohort
From BIG 02-98, patients who had formalin-fixed paraf-
fin-embedded (FFPE) primary tissue submitted centrally
and for which there was sufficient remaining tumor tis-
sue for TP53 gene analysis were selected for the p53
biomarker study. A total of 666 cases were selected, of
whom 520 were successfully analyzed for exons 5 to 8.
The substudy population was representative of the
entire BIG-02-98 population for all baseline patient and
tumor characteristics. [See Additional file 1.] The trans-
lational study was approved by the Ethics Committee of
the Jules Bordet Institute (IJB) in Brussels, Belgium,
which served as the coordinating center for this retro-
spective study.
Tumor material and immunohistochemistry
The study protocol requested central collection of one
FFPE tumor sample for each patient. Slides were pre-
pared by the Pathology Department at IJB and sent to
the European Institute of Oncology (EIO), Milan, Italy
for central pathology analyses and genomic DNA extrac-
tion. Slide review, IHC and fluorescence in situ hybridi-
zation (FISH) were performed on whole tissue sections
from FFPE samples. Tumor grade was centrally
reviewed. Unstained tumor specimens were stained for
estrogen receptor (ER), progesterone receptor (PgR),
human epidermal growth factor receptor 2 (HER2) and
Ki-67 (all specific monoclonal or polyclonal (for HER2)
antibodies were purchased from Dako, Glostrup, Den-
mark). IHC results were reported as the percentage of
invasive tumor cells showing definite immunoreactivity.
FISH was performed for HER2 according to the manu-
facturer’s instructions (Abbott-Vysis Inc., Downers
Grove, IL, USA). Thresholds for positivity were defined
as: ER: ≥ 1%; PgR: ≥ 1%, HER2: IHC 3+ (more than 10%
invasive tumor cells with intense and circumferential
membrane staining) or 2+ and FISH positive (HER2:
CEP17 ratio > 2). The Ki-67 threshold used in the dis-
tinction of luminal A and luminal B subtypes was
defined as ≥ 14%, based on published work by Cheang
et al. [30].
Four breast cancer subtypes were defined using central
laboratory defined parameters, as follows: (1) highly
endocrine responsive (luminal A): ER-positive, PgR-posi-
tive, HER2-negative and Ki-67 low; (2) incompletely
endocrine responsive (luminal B): ER-positive and PgR-
negative, independent of other parameters, or ER-posi-
tive, PgR-positive and at least one of grade 3, HER2-
positive and/or Ki-67 high; (3) HER2-positive: ER-nega-
tive, PgR-negative and HER2-positive; and (4) triple-
negative: ER-negative, PgR-negative and HER2-negative.
[See Additional file 2.]
DNA extraction
Genomic DNA was extracted from two to three serial
sections of FFPE-archived specimens (10 μm thick).
Dewaxing was obtained by xylene and ethanol with
alternating vortexing and centrifuging. DNA was then
extracted with a commercially available kit (DNeasy
Blood & Tissue Kit, Qiagen N.V., Venlo, The Nether-
lands). Tissue was lysed overnight with proteinase K
digestion in denaturing condition and DNA bound to
spin column silica membrane. The contaminants were
washed away and DNA was eluted with 100 μL of sterile
distilled water. The final DNA concentration was evalu-
ated by OD260 (GeneQuant II, Pharmacia Biotech,
Uppsala, Sweden).
TP53 mutation screening and sample classifications
Genomic DNA was screened for TP53 mutations at
IARC. Exons 5 to 8 of TP53 were analyzed in all avail-
able samples by polymerase chain reaction (PCR). Exon
Fernández-Cuesta et al. Breast Cancer Research 2012, 14:R70
http://breast-cancer-research.com/content/14/3/R70
Page 3 of 13
4 was analyzed in a subset of samples with sufficient
available tumor material. Direct sequencing of genomic
DNA has been described in the IARC protocol [31].
Mutations were screened on both DNA strands and
were confirmed in an independent PCR product.
TP53 gene sequencing reported all variations. These
variations were used to classify samples according to
p53 protein status, which take into account the pre-
dicted impact of genetic variations on p53 proteins.
Thus, a variation is considered a mutation when it is
predicted to modify p53 protein sequence. Tumors were
classified as wild-type p53 or mutated p53. (See Table
1.)
Mutated p53 protein status was further subcategorized
as missense or truncating. (See Table 1.) Missense muta-
tions produce proteins that are changed by one amino
acid. Truncating mutations include nonsense, frameshift
insertions and deletions, and variations in consensus
splice sites. Annotations from the IARC TP53 Database
[19] were used to also stratify missense mutations
according to their transactivation activities in yeast func-
tional assays, or to their position inside or outside DNA-
binding motifs (L1/L2/L3 loops) [17,32]. Sample sub-
classification was done when sequencing result was
obtained for all exons 5 to 8. Two samples were not
subclassified because the sequencing result was missing
for one exon.
Statistical analyses
The study was based on the hypotheses that p53
mutated tumors would have the worst clinical outcome
and the largest benefit from the addition of docetaxel.
Statistics were performed using SAS version 9.1. (SAS
Institute Inc., Cary, NC, USA) and Minitab version 13
software (Minitab Inc., State College, PA, USA). The
chi-square test was used to compare the distributions of
clinicopathological parameters by randomized treatment
arm (anthracycline control arms, A and AC, versus
taxane arms, A-T and AT), and by p53 status (wild-type
p53 versus p53 mutated). Fisher’s exact test was used to
compare the distributions of clinicopathological para-
meters by p53 mutation subcategorization (wild-type
p53 versus missense mutation; wild-type p53 versus
truncating mutation).
DFS was calculated from the date of randomization to
the date of disease recurrence, second primary cancer or
death from any cause. OS was calculated from the date
of randomization to the date of last follow-up or death
from any cause. Survival curves were estimated using
the method of Kaplan-Meier and curves for different
classifications were compared using the log-rank test.
Multivariate Cox regression models, with backward
selection, were used to test the prognostic effect of p53
status after adjusting for other important prognostic
variables. Multivariate DFS analysis included patient
characteristics (age, menopausal status, body mass index
(BMI)), tumor characteristics (tumor size, number of
positive lymph nodes, histopathological type, histological
grade, IHC defined subtypes, p53 mutation status) and
treatment characteristics (mastectomy, radiotherapy, use
of tamoxifen, chemotherapy arm (A+AC versus A-T
+AT arms), chemotherapy schedule (sequential or
concurrent)).
Results
Results of BIG 02-98
After an 8-year median follow-up, the second efficacy
results of BIG 02-98 did not show significant improve-
ment in DFS from the incorporation of docetaxel com-
pared with the doxorubicin-based control (hazard ratio
(HR) = 0.91, 95% confidence interval (CI) = 0.80 to 1.05,
P = 0.187). However, sequential A-T significantly
improved DFS compared with the sequential control
arm A (HR = 0.81, 95% CI = 0.67 to 0.99, P = 0.036),
and significantly improved both DFS (HR = 0.84, 95%
CI = 0.72 to 0.99, P = 0.035) and OS (HR = 0.79, 95%
Table 1 p53 mutation status and prevalence.
p53 status Rules Prevalence
(%)
N = 520
Wild-type p53 No variation*; synonymous variations; intronic variations outside splice sites 435 (83.6%)
Mutated p53 Any variation predicted to modify protein sequence: missense, nonsense, insertion, deletion, variation in
splice sites
85 (16.3%)
Subcategorization of mutated p53
Missense mutation Protein changed by one amino acid 64 (12.3%)
Truncating
mutation
Nonsense, insertion**, deletion**, variation in splice sites 19 (3.6%)
Not classified*** 2 (0.4%)
Sample classification status is based on the predicted impact of mutation on p53 protein. Only exons 5 to 8 and splicing junctions were sequenced.
*Any nonsynonymous variation in exon 5 to 8. **All insertion and deletion found in this series induced a frameshift.. ***Not subclassified because the sequencing
result was missing for one exon.
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CI = 0.65 to 0.98, P = 0.028) compared with concurrent
AT [33].
p53 substudy cohort
From BIG 02-98, 2172 of 2887 (75%) patients had FFPE
primary tissue submitted centrally. Of these 2172
patients, 666 patients had sufficient remaining tumor
tissue for TP53 gene analysis, of whom 520 (18% of the
original trial population) were successfully analyzed for
exons 5 to 8. Of the 520 tumors, 116 were also analyzed
for exon 4. The remaining 142 samples could not be
analyzed due to poor DNA quality.
The substudy population was representative of entire
BIG-02-98 population for all baseline patient and tumor
characteristics. [See Additional file 1.] DFS was similar
for patients included and not included in this substudy.
[See Additional file 3.]
The majority of patients in this p53 substudy were less
than 50 years old, premenopausal and nonobese. (See
Table 2.) Most tumors were infiltrating ductal carci-
noma, ≤ 20 mm, grade 2 or 3, ER-positive and HER2-
negative. Regarding the IHC-defined breast cancer sub-
types, most tumors were classified as luminal B, of
which, 59 were positive for HER2 (19%, not shown).
Between the control (A + AC) and docetaxel (A-T +
AT) arms, characteristics differed for ER/PgR status and
IHC-defined subtypes: a significantly higher proportion
of ER- and PgR-negative tumors were present in the
control arms (P = 0.046). In keeping with this, there was
a trend for a higher proportion of the HER2 subtype
and triple-negative subtype in the control arms (P =
0.052).
p53 mutations and sample characteristics
A total of 96 variations within exon 5 to 8 were found
in 90 samples (90 of 520, 17%). [See Additional file 4 for
full data.] In the 90 patients with a TP53 gene variation,
85 patients had only one variation, four patients had
two variations, and one patient had three variations.
Most variations were missense and were located at clas-
sical hotspot codons, except for one specific mutation at
codon 259 (p.D259N) that was found in six samples. It
is of note that no in-frame deletions or insertions were
found in these series. In the patient with three gene var-
iations, each of the three variations was located in
introns and was predicted to not affect protein sequence
(not shown).
TP53 gene status was used to predict p53 protein sta-
tus and classify patients as wild-type or mutated. Nonsy-
nonymous mutations were further distinguished as
missense or truncating. (See Table 1.)
The presence of a mutated p53 protein was associated
with older age, postmenopausal status, ductal morphol-
ogy, higher tumor grades and ER/PgR negativity. (See
Table 3.) A strong correlation between IHC-defined
subtypes and p53 status was found: the proportion of
p53 mutated samples in each IHC subtype showed that
the HER2 and triple-negative subtypes had the highest
rates of p53 mutations, with 22% (7 of 32) and 36% (24
of 66) of mutated samples respectively, compared to
10% (8 of 84) in the luminal A subtype and 13% (45 of
315) in the luminal B subtype.
Prognostic value of p53 mutations
At an 8-year median follow-up, the number of DFS
events in the entire BIG 02-98 population was 916 of
2887 patients (32%). In this p53 substudy cohort, the
number of DFS events was 164 of 520 patients (32%).
Survival curves (DFS and OS) for patients included in
this p53 substudy are shown in Figure 1. There was no
statistically significant difference in DFS or OS based on
p53 mutated status. However, when subclassifying muta-
tions, truncating mutations but not missense mutations
were found to be associated with a significant reduction
in DFS and OS (P < 0.001). Further stratification of mis-
sense mutations, based on their transactivation capaci-
ties or location in the 3D structure of p53 protein, did
not reveal classes of mutations with different prognostic
value (data not shown). Thus, in univariate analysis only
p53 truncating mutations were associated with poor
survival.
Multivariate DFS analysis was performed including
patient characteristics (age, menopausal status, BMI),
tumor characteristics (tumor size, number of positive
lymph nodes, histopathological type, histological
grade, IHC-defined subtypes, p53 mutation status) and
treatment characteristics (mastectomy, radiotherapy,
use of tamoxifen, chemotherapy arm (A+AC versus A-
T+AT arms), chemotherapy schedule (sequential or
concurrent)). The presence of p53 truncating muta-
tions was associated with an increased risk of recur-
rence (HR = 3.21, 95% CI 1.74 to 5.94, P = 0.0002)
compared to the absence of mutation within exons 5
to 8. In this multivariate model, only p53 truncating
mutations, number of positive lymph nodes (≥ 4
nodes: HR = 1.99, 95% CI: 1.44 to 2.76, P < 0.0001)
and the HER2 subtype (HR = 2.36, 95% CI 1.21 to
4.60, P = 0.0122) had independent prognostic value.
(See Table 4.)
Similar results were obtained for OS. In a multivariate
OS analysis, p53 truncating mutations were associated
with poor OS compared to the absence of mutation
within exons 5 to 8 (HR = 2.75, 95% CI: 1.50 to 5.04, P
= 0.0011).
Predictive value of p53 status
In keeping with efficacy results in the entire BIG 02-98
population, this substudy population showed a favorable
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Table 2 Characteristics of patients and samples in the p53 substudy.
Arm (A+AC)
Anthracycline
Control Arms
N = 167
Arm (AT+A-T)
Docetaxel Arms
N = 353
Total
N = 520
P value
(Chi-square Test)*
Age (years) Median 48 49 49 0.193
Range 27-66 26-70 26-70
< 35 12 (7.2%) 22 (6.2%) 34 (6.5%)
35-49 88 (52.7%) 167 (47.3%) 255 (49.0%)
50-65 65 (38.9%) 148 (41.9%) 213 (41.0%)
> 65 2 (1.2%) 16 (4.5%) 18 (3.5%)
Menopausal status Premenopausal 104 (62.3%) 212 (60.0%) 316 (60.7%) 0.628
Postmenopausal 63 (37.7%) 141 (39.9%) 204 (39.3%)
Body Mass Index (BMI) Nonobese (BMI < 30) 135 (80.8%) 283 (80.2%) 418 (80.4%) 0.858
Obese (BMI > = 30) 32 (19.2%) 70 (19.8%) 102 (19.6%)
Histopathology Infiltrating ductal ca. 139 (83.2) 285 (80.7%) 424 (81.5%) 0.441
Infiltrating lobular ca. 13 (7.8%) 40 (11.3%) 53 (10.2%)
Other 15 (8.9%) 28 (7.9%) 43 (8.3%)
Tumor size (pT) T1 55 (32.9%) 96 (27.2%) 151 (29.0%) 0.397
T2 102 (61.1%) 224 (63.4%) 326 (62.7%)
T3 9 (5.4%) 29 (8.2%) 38 (7.3%)
Missing 1 (0.6%) 4 (1.1%) 5 (0.9%)
Number of positive lymph nodes 1-3 83 (49.7%) 189 (53.5%) 272 (52.3%) 0.610
≥ 4 84 (50.3%) 164 (46.4%) 248 (47.7%)
Histopathologic grade G1 9 (5.4%) 27 (7.6%) 36 (6.9%) 0.204
G2 77 (46.1%) 153 (43.3%) 230 (44.2%)
G3 76 (45.5%) 170 (48.1%) 246 (47.3%)
Missing 5 (3.0%) 3 (0.8%) 8 (1.5%)
ER/PgR status ER+/PgR+ 106 (63.5%) 265 (75.1%) 371 (71.3%) 0.046
ER+/PgR- 12 (7.2%) 20 (5.7%) 32 (6.1%)
ER-/PgR- 40 (23.9%) 58 (16.4%) 98 (18.8%)
Other/missing 9 (5.4%) 10 (2.8%) 19 (3.6%)
HER2 status HER2- 126 (75.4%) 288 (81.6%) 414 (79.6%) 0.113
HER2+ 33 (19.7%) 58 (16.4%) 91 (17.5%)
Missing 8 (4.8%) 7 (1.9%) 15 (2.9%)
IHC subtypes** Luminal A 28 (16.8%) 56 (15.9%) 84 (16.1%) 0.052
Luminal B 88 (52.7%) 227 (64.3%) 315 (60.6%)
HER2 15 (8.9%) 17 (4.8%) 32 (6.2%)
Triple-negative 25 (14.9%) 41 (11.6%) 66 (12.7%)
Missing 11 (6.6%) 12 (3.4%) 23 (4.4%)
p53 status Wild-type 134 (80.2%) 301 (85.3%) 435 (83.6%) 0.147
Mutated 33 (19.8%) 52 (14.7%) 85 (16.3%)
Hormonotherapy use Received tamoxifen 118 (70.6%) 274 (77.6%) 392 (75.4%) 0.085
Did not receive
tamoxifen
49 (29.4%) 79 (22.4%) 128 (24.6%)
*Comparison of anthracycline control arms and taxane arms. **See Additional file 2 for definition of IHC subtypes. A, doxorubicin; C, cyclophosphamide; ER,
estrogen receptor; IHC, immunohistochemistry; PgR, progesterone receptor: T, docetaxel.
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trend but not a significant benefit in DFS from the addi-
tion of docetaxel (HR = 0.77, 95% CI: 0.56 to 1.06).
Analyses of the predictive value of p53 status for predic-
tion of improvement in DFS from addition of docetaxel
are shown in Figure 2a (p53 wild-type and mutant) and
Figure 2b (p53 wild-type, missense and truncating muta-
tions). None of these predictive analyses were statisti-
cally significant.
Table 3 Associations between p53 protein status and clinicopathological parameters.
Wild-type
p53
N = 435
p53
mutated*
N = 85
P
value**
Missense
mutation
N N = 64****
P
value***
Truncating
mutation
N = 19****
P
value***
Age < 35 31 (7.1%) 3 (3.5%) 0.0045 2 (3.1%) 0.0061 1 (5.2%) 0.6432
35-49 219 (50.3%) 36 (42.3%) 26 (40.6%) 10 (52.6%)
50-65 175 (40.2%) 38 (44.7%) 29 (45.3%) 7 (36.8%)
> 65 10 (2.3%) 8 (9.4%) 7 (10.9%) 1 (5.2%)
Menopausal status Premenopausal 248 (57.0%) 38 (44.7%) 0.0768 27 (42.2%) 0.0800 11 (57.9%) 0.7279
Postmenopausal 163 (37.5%) 43 (55.3%) 33 (51.6%) 8(42.1%)
Not known 24 (5.5%) 4 (4.7%) 4 (6.3%) 0
Body Mass Index (BMI) Nonobese (< 30) 352 (80.9%) 66 (77.6%) 0.487 52 (81.3%) 1.0000 12 (63.2%) 0.0744
Obese (> = 30) 83 (19.1%) 19 (22.3%) 12 (18.8%) 7 (36.8%)
Histopathology Infiltrating ductal
ca.
347 (79.8%) 77 (90.6%) 0.0256 57 (89.1%) 0.0866 18 (94.7%) 0.2922
Infiltrating lobular
ca.
51 (11.7%) 2 (2.3%) 2 (3.1%) 0
Other 37 (8.5%) 6 (7.1%) 5 (7.8%) 1 (5.3%)
Tumor size (pT) T1 129 (29.6%) 22 (25.9%) 0.6070 15 (23.4%) 0.3858 6 (31.6%) 0.6489
T2 268 (61.6%) 58 (68.2%) 45 (70.3%) 13 (68.4%)
T3 34 (7.8%) 4 (4.7%) 3 (4.7%) 0
Missing 4 (0.9%) 1 (1.2%) 1 (1.6%) 0
Number of positive lymph
nodes
1-3 230 (52.9%) 42 (49.4%) 0.5587 34 (53.1%) 1.0000 8 (42.1%) 0.4825
> = 4 205 (47.1%) 43 (50.6%) 30 (46.9%) 11 (57.9%)
Histopathological grade G1 34 (7.8%) 2 (2.3%) <
0.0001
1 (1.6%) 2.977E-
04
1 (5.3%) 0.0078
G2 208 (47.8%) 22 (25.9%) 18 (28.1%) 3 (15.8%)
G3 186 (42.7%) 60 (70.6%) 44 (68.8%) 15 (79.0%)
Missing 7 (1.6%) 1 (1.2%) 1 (1.6%) 0
ER/PgR status ER+/PgR+ 322 (74.0%) 49 (57.6%) <
0.0001
42 (65.6%) 0.0415 6 (31.6%) 1.424E-
04
ER+/PgR- 28 (6.4%) 4 (4.7%) 2 (3.1%) 2 (10.5%)
ER-/PgR- 67 (15.4%) 31 (36.5%) 19 (29.7%) 11 (57.9%)
Other 18 (4.1%) 1 (1.2%) 1 (1.6%) 0
HER2 status HER2 - 350 (80.4%) 64 (75.3%) 0.1848 48 (75.0%) 0.2145 15 (79.0%) 0.5460
HER2+ 71 (16.3%) 20 (23.5%) 15 (23.4%) 4 (21.0%)
Missing 14 (3.2%) 1 (1.2%) 1 (1.6%) 0
IHC subtypes Luminal A 76 (36.8%) 8 (9.4%) <
0.0001
6 (9.4%) 0.0155 2 (10.5%) 1.592E-
04
Luminal B 270 (62.1%) 45 (52.9%) 38 (59.4%) 6 (31.6%)
HER2 25 (5.7%) 7 (8.2%) 4 (6.3%) 2 (10.5%)
Triple-negative 42 (9.6%) 24 (28.2%) 15 (23.4%) 9 (47.4%)
Missing 22 (5.0%) 1 (1.2%) 1 (1.6%) 0
*Any non-synonymous variation in exon 5 to 8. **P value-chi-square test: comparison of wild-type p53 and p53 mutated. ***P value-Fisher’s exact test:
comparison of wild-type p53 and p53 mutation (missense or truncating). ****Of 85 p-53 mutations, 83 were classified as mutated (N = 64) or truncating (N = 19),
and 2 were not subclassified (see Methods section). ER, estrogen receptor; IHC, immunohistochemistry; PgR, progesterone receptor.
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Discussion
In this retrospective exploratory study performed on
samples collected in the context of the prospective BIG
02-98 randomized phase III clinical trial, we show that
p53 truncating mutations have a significant independent
prognostic value in node-positive breast cancer patients
treated with adjuvant chemotherapy. However, no signif-
icant value for p53 status in predicting response to doc-
etaxel therapy was found in this cohort.
TP53 mutations were detected in a minority of
patients (16.3%). Most mutations (75%) were missense,
while the remaining (22%) were truncating. The preva-
lence and type of TP53 mutations found are similar
with previous studies that have restricted their analysis
to exons 5 to 8 and used DNA as starting material (73%
of missense mutation in IARC TP53 Database, R15).
The presence of mutated p53 was associated with
patient characteristics of increased age and
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Figure 1 Prognostic value of p53 mutations. Survival in p53 wild-type versus p53 mutated cases, (a) DFS and (b) OS. Survival in p53 wild-
type versus missense versus truncated mutations, (c) DFS and (d) OS. DFS, disease-free survival; OS, overall survival.
Table 4 Multivariate Cox proportional hazards models of
disease-free survival.
HR (95% CI) P value
p53 protein status
Wild-type p53 1
Missense 0.773 (0.457-1.308) 0.3366
Truncating 3.213 (1.740-5.935) 0.0002
Number of positive lymph nodes
1-3 1
≥ 4 1.992 (1.439-2.758) < 0.0001
IHC subtypes
Luminal A 1
Luminal B 1.237 (0.768-1.992) 0.3812
HER2-positive 2.355 (1.205-4.603) 0.0122
Triple-negative 1.086 (0.580-2.032) 0.7965
CI, confidence index; IHC, immunohistochemistry; HR, hazard ratio.
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postmenopausal status, and tumor characteristics of
ductal morphology, higher grades and ER/PR negativity,
in agreement with previous studies [5,34,35]. The high-
est rates of mutations were seen in the HER2 and triple-
negative subtypes, as reported in other studies
[12,36,37].
Most mutations were found at classical hotspot
codons and were loss of function mutations as assessed
in yeast functional assays [17]. The only exception was a
specific hotspot at codon 259, which was found in six
samples. The resulting mutation, p.D259N, has been
infrequently reported in human cancers (only 14 occur-
rences in the IARC TP53 Database, none in breast can-
cers [19]) and retains partial activity in yeast functional
assays [17]. We ruled out PCR contamination and tech-
nical causation. The origin of this mutation remains to
be determined.
Truncating mutations had an independent prognostic
value against a large range of clinical and molecular
variables. These results confirm and extend those
obtained in previous studies, including our own per-
formed on a large consecutive series of breast cancers
[5]. Interestingly, missense mutations were not
associated with poor survival in the current study. Dis-
crimination between missense mutations according to
location inside or outside DNA-binding motifs, muta-
tions that retain or do not retain transactivation activ-
ities, or have dominant-negative effects did not
differentiate missense mutations with poorer survival
(data not shown). This is in contrast with our previous
study, which showed that missense mutations within
DNA-binding motifs (but not those outside these
motifs) and non-missense mutations were associated
with poor prognosis [5]. There was no obvious differ-
ence between the type of missense mutation found in
this series and earlier studies to explain these discrepant
results. Inconsistency of results regarding the prognostic
value of missense mutations across studies may be due
to the fact that missense mutations may retain some
activity, beyond the specific activity detectable in a parti-
cular study. This is in contrast to more consistent
results for truncating mutations, which are true loss of
function mutations.
The multivariate model for the prognostic value of
p53 included many variables, notably it included BMI-
and IHC-defined molecular subtypes. BMI was included
1.00.0 2.0
A1+A2 C HR (CI) C    A1+A2
p53 status O/N O/N better    better
wild-type 47 / 134 42 / 153 0.75(0.49,1.14)
missense 7 / 24 1 / 13 0.27(0.03,2.17)
truncating 7 / 9 5 / 8 0.53(0.15,1.80)
Total 61 / 167 48 / 174 0.69(0.47,1.01)
Heterogeneity test X
2
1 = 1.12 , P =0.2899
1.00.0 2.0
A1+A2 B+C HR (CI) B+C    A1+A2
p53 status O/N O/N better    better
wild-type 47 / 134 89 / 301 0.82(0.58,1.17)
missense 7 / 24 9 / 40 0.80(0.30,2.14)
truncating 7 / 9 5 / 10 0.39(0.11,1.35)
Total 61 / 167 103 / 351 0.78(0.57,1.07)
Heterogeneity test X
2
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p53 status O/N O/N better    better
wild-type 47 / 134 47 / 148 0.90(0.60,1.35)
missense 7 / 24 8 / 27 1.08(0.39,2.98) >
truncating 7 / 9 0 / 2 0.00(0.00,   -   )
Total 61 / 167 55 / 177 0.87(0.60,1.25)
Heterogeneity test X
2
1 = 0.11 , P =0.7431
Predictive values of p53 protein status on disease free survival 
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wild-type 47 / 134 89 / 301 0.82(0.58,1.17)
mutated 14 / 33 14 / 52 0.59(0.28,1.24)
Total 61 / 167 103 / 353 0.77(0.56,1.06)
Heterogeneity test X
2
1 = 0.62 , P =0.4314
1.00.0 2.0
A1+A2 C HR (CI) C    A1+A2
p53 status O/N O/N better    better
wild-type 47 / 134 42 / 153 0.75(0.49,1.14)
mutated 14 / 33 6 / 21 0.61(0.23,1.60)
Total 61 / 167 48 / 174 0.73(0.50,1.06)
Heterogeneity test X
2
1 = 0.15 , P =0.7016
1.00.0 2.0
A1+A2 B HR (CI) B    A1+A2
p53 status O/N O/N better    better
wild-type 47 / 134 47 / 148 0.90(0.60,1.35)
mutated 14 / 33 8 / 31 0.56(0.24,1.34)
Total 61 / 167 55 / 179 0.82(0.57,1.19)
Heterogeneity test X
2
1 = 0.93 , P =0.3359
Figure 2 Value of p53 mutations in predicting DFS benefit from adding docetaxel to control anthracycline-based therapy. (a) Wild-type
p53 versus mutant p53 protein. (b) p53 wild-type versus missense mutant versus truncated mutant. Treatment comparisons were made between
(i) anthracycline control arms (A+AC) and sequential docetaxel (A-T); (ii) anthracycline control arms (A+AC) and concurrent docetaxel (AT); and
(iii) anthracycline control arms (A+AC) and combined docetaxel arms (A-T+AT). A, doxorubicin; C, cyclophosphamide; DFS, disease-free survival;
T, docetaxel.
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as obesity was found to have an independent poor prog-
nostic value in this trial as well as in other studies
[38,39]. In this substudy however, BMI had no indepen-
dent prognostic value. The independent predictors of
poor DFS and OS were p53 truncating mutations, high
number of positive lymph nodes and the HER2 subtype.
It is of note that BIG 02-98 was conducted prior to the
use of adjuvant HER2-targeted therapies. The prognostic
value of HER2 subtype is thus independent of HER2-tar-
geted treatment in these patients. Interestingly, the tri-
ple-negative subtype did not have prognostic value in
the univariate analysis and had no independent prognos-
tic value. Many studies in early breast cancer have
reported that the triple-negative subtype is particularly
aggressive and associated with a high rate of recurrence
and early death. A possible explanation for the lack of
adverse outcomes in the triple-negative subtype in the
current study may be the limited sample size.
In this study, p53 mutations had no significant predic-
tive value. This study adds to the conflicting body of
clinical evidence regarding the potential clinical role of
p53 as a single biomarker for prediction of chemother-
apy response. Other studies assessing TP53 gene
sequence have presented data in support of reduced
anthracycline activity in TP53 mutated tumors [9-11].
However, the predictive correlations were not robust
enough for TP53 gene status, as a single biomarker, to
be considered a clinical tool to guide treatment deci-
sions. Three recent neoadjuvant studies in early breast
cancer have reported a predictive role for TP53 muta-
tions. In a phase II Xeloda in Neoadjuvant (XeNa) trial
assessing capecitabine and docetaxel, with trastuzumab
if HER2-positive, a secondary study endpoint was eva-
luation of TP53 status and response to chemotherapy
[12]. TP53 mutations, detected by AmpliChip p53
(Roche Diagnostics, Pleasanton, CA, USA), correlated
significantly with improved pathological complete
response rate compared with TP53 wild-type (30% ver-
sus 10%, respectively, P = 0.0032). In a study using
dose-dense epirubicin-cyclophosphamide, TP53 muta-
tions were detected using a yeast functional assay.
Pathological complete responses, which occurred in 19%
(15 of 80 patients), were restricted to tumors with a
TP53 mutation (28 of 80 patients) [40]. In another small
study that included only triple-negative breast cancers
patients treated with neoadjuvant cisplatin, nonsense
and frameshift TP53 mutations were associated with
good response to treatment [41]. The lack of a control
arm in these three studies limits interpretation of prog-
nosis versus prediction, and of general versus specific
agent chemosensitivity.
An important recent study is the neoadjuvant phase
III EORTC 10994/BIG 00-01 trial which is the only
study to be prospectively powered to assess the value of
p53 status for prediction of docetaxel benefit [14]. Using
an RNA-based technique that detects functionally
important p53 mutations, the prognostic role of p53
was confirmed, but p53 was not predictive of response
or resistance to docetaxel.
The negative results from the prospective EORTC
study and our BIG 02-98 substudy, with a background
of inconsistent results, suggest that p53 status as an iso-
lated marker may be inadequate to predict treatment
response to docetaxel. p53 is not a drug target, but
rather a surrogate measure for cellular capacity for
apoptosis, and cell proliferation control. The complexity
of p53 function, post-transcriptional effects and up- and
down-stream signaling pathway cross-talks may limit
the power of p53 status as a sole biomarker, in particu-
lar for treatments that combine drugs that have different
mode of action towards p53.
A strength of the current study is the biological dis-
tinction of nonsynonymous mutations as missense (in
and out of DNA-binding motifs) and truncating. Group-
ing all mutations together for assessment of outcomes
assumes homogeneity in the impact of different muta-
tions. Use of a dichotomous classification did not iden-
tify a prognostic or predictive correlation, whereas the
more specific classification system revealed the indepen-
dent prognostic significance value of the truncating
mutations. A limitation of this approach however, is
that such a cohort contain few patients, limiting to
some degree the confidence with which conclusions
may be drawn for the subsets.
The presumption of a homogeneous role of p53 across
diverse biological subgroups may also account for incon-
sistent findings. In distinct breast cancer subgroups, p53
mutations may have variable prevalence, and impact dif-
ferently on prognosis and treatment sensitivity. As part
of the I-SPY neoadjuvant initiative (CALGB 150007), a
recent study reported TP53 status determined by gene
chip technology and sequencing in women treated with
anthracycline- then taxane-based therapy [42]. In the
luminal A subtype, 14 of 48 patients has a TP53 muta-
tion, and there was no differential efficacy of either
treatment based on TP53 status. In contrast, TP53
mutations had a much higher prevalence in the luminal
B, basal-like and HER2 subgroups, in whom, anthracy-
cline efficacy was independent of TP53 status and tax-
ane efficacy was greater in the presence of wild-type
TP53. In the current study, mutated p53 was indeed
more prevalent in HER2 and triple-negative subtypes.
However, small numbers precluded analyses by
subgroups.
A critical issue in the clinical translation of p53 is the
impact of gene variations on p53 protein function.
Herein the classification of p53 mutations was based on
estimated downstream impact on protein sequence. A
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reported alternative for identification of ‘functional’ loss
of wild-type p53 is a p53 transcriptional fingerprint. Sev-
eral gene expression signatures have been reported that
distinguish between wild-type and mutant p53
[36,43,44]. Interestingly some TP53 wild-type tumors
expressing the mutation-associated 32-gene signature
behaved aggressively, while some TP53 mutant tumors
lacking the signature had favorable outcome [43]. In
another recent report, a 39-gene and a 30-gene p53 sig-
nature were developed in ER-positive and -negative
breast cancer, respectively [45]. It is of note that there
was no overlap in genes across the two signatures. The
ER-positive p53 signature in ER-positive disease was
predictive of poor prognosis and increased chemosensi-
tivity. The ER-negative p53 signature in ER-negative dis-
ease was associated with improved prognosis, but had
no prediction of treatment response. Downstream func-
tional assessment of p53 status may also capture the
impact of other p53 variables that may influence tumor
outcome and treatment sensitivity, such as p53 codon
polymorphisms [46] and p53 protein isoforms [47].
Further studies using downstream functional assessment
of p53 status are thus needed to better understand the
impact of p53 mutations on tumor phenotype.
The current study has limitations. This is a retrospec-
tive exploratory analysis, which was not considered in
the initial statistical trial design or trial sample size
determination. In the trial, all patients received polyche-
motherapy so it is impossible to determine interactions
between single-agent activity and p53 status. Only exons
5 to 8 of TP53 gene were screened for mutation due to
the limited amount of DNA available. According to pre-
vious studies, up to 20% of mutations may fall outside
these exons (IARC TP53 Database, R15). To evaluate
the number of misclassified samples due to this partial
sequencing, 84 samples were successfully sequenced for
exon 4, the next most mutated exon in breast cancers
(IARC TP53 Database, R15). One truncating and 13
missense mutations were found. Since all missense
mutations retained transactivation activity, only 1 of 84
(1.2%) was considered a true deleterious mutation. As
mutations in other exons are expected to be rare (less
than 1% of mutations reported in breast cancers fall out-
side exons 4 to 8), we estimate that less than 2% of sam-
ples may have been misclassified as wild-type in our
series.
Conclusions
Despite an abundant literature on the prognostic and
predictive value of p53 status in breast cancer, a limited
number of studies have used gene sequencing to assess
p53 status and even fewer studies have been performed
in the context of controlled clinical trials. The results
confirm that loss of wild-type p53 through protein
truncating mutations is associated with poor prognosis.
Our results point to differences in the prognostic value
of different types of mutations and to the difficulty of
assessing the predictive value of a molecular marker in
treatment regimens that combine drugs with different
modes of action regarding this marker.
Additional material
Additional file 1: Table S1, Characteristics of patients analyzed for
TP53 mutations compared with the entire BIG-02-98 cohort. From
BIG 02-98, 666 patients with centrally submitted FFPE primary tissue and
sufficient remaining tumor tissue for TP53 gene analysis were selected for
the p53 biomarker study. Of these, 520 tumors were successfully
analyzed for exons 5-8. This table contains baseline patient and tumor
characteristics, showing that the substudy population was representative
of the entire BIG-02-98 population.
Additional file 2: Table S2, Immunohistochemistry (IHC) subtypes as
defined in this study. Four breast cancer subtypes (luminal A, luminal B,
HER2-positive and triple-negative) were defined using central laboratory
defined parameters (ER, PgR, HER2, grade and Ki-67).
Additional file 3: Figure S1, Representativeness of the p53 cohort:
disease-free survival for patients included in the p53 substudy and
patients not included in the p53 substudy from the BIG 02-98 trial.
Kaplan-Meier curve confirming similar disease-free survival for BIG 02-98
patients included and not included in this substudy.
Additional file 4: Table S3, TP53 gene variations found in the p53
substudy. From 520 analyzed tumors, 96 variations within exon 5 to 8
were found in 90 samples (90 of 520, 17%). This table lists TP53 gene
variation data for the 90 samples. Eighty-five patients had only one
variation, four patients (ID: 10120, 10202, 42618, 62514) had two
variations, and one patient had three variations (ID: 22205).
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